tbuckley/cabot-search huggingface dataset:
Journal of Surgical Research, Philadelphia
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (PAH): insights from the randomised controlled griphon trial with selexipag
Journal: Thorax (2016)

AbstractThe GRIPHON study was sponsored by Actelion Pharmaceuticals Ltd. G Coghlan: Consulting fees: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, GenenTech, United Therapeutics. Speaker’s honoraria and research grants: Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Bayer HealthCare, United Therapeutics. S Gaine: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, United Therapeutics, Novartis, Pfizer. Steering Committee membership: Actelion Pharmaceuticals Ltd, GlaxoSmithKline, United Therapeutics, Novartis. R Channick: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, United Therapeutics. Steering Committee membership: Actelion Pharmaceuticals Ltd. L Di Scala: Employee Actelion Pharmaceuticals Ltd. N Galié: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer. Steering Committee membership: Actelion Pharmaceuticals Ltd. HA Ghofrani: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, GlaxoSmithKline, Merck & Co, Novartis Corporation, Pfizer Inc. Steering Committee membership: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, GlaxoSmithKline, Merck & Co, Novartis Corporation, Pfizer Inc. MM Hoeper: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer, Gilead Sciences. Steering Committee membership: Actelion Pharmaceuticals Ltd. I Lang: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Novartis Corporation, United Therapeutics. Steering Committee membership: Actelion Pharmaceuticals Ltd. V McLaughlin: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, United Therapeutics, Ikaria, Novartis. Steering Committee membership: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, United Therapeutics, Ikaria. R Preiss: Employee Actelion Pharmaceuticals Ltd. LJ Rubin: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, GeNO Pharmaceuticals, Lung Biotechnology, Gilead Sciences Inc, United Therapeutics. Steering Committee membership: Actelion Pharmaceuticals Ltd. G Simonneau: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly & Co, GlaxoSmithKline, Novartis Corporation, Pfizer Inc. Steering Committee membership: Actelion Pharmaceuticals Ltd. O Sitbon: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer Inc, United Therapeutics. Steering Committee membership: Actelion Pharmaceuticals Ltd.
THE SANITATION OF EATING UTENSILS
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II study of tivozanib in patients with metastatic and non-resectable soft tissue sarcomas.
Authors: Mark Agulnik, Mohammed M. Milhem, Alfred Rademaker, Catherine Humphreys, Susan E. Abbinanti, Lauren Elizabeth Nye, Rasima Cehic, Ariel Polish, Claudia Roxana Vintilescu, Thomas McFarland, Keith M. Skubitz, Steven Ian Robinson, Scott H. Okuno, Brian Andrew Van Tine
Journal: Journal of Clinical Oncology (2015)

10515 Background: Despite a multi-modality approach, many patients (pts) with early stage soft tissue sarcomas (STS) will develop recurrent or metastatic disease. Treatment options for these pts are limited, thus necessitating new antitumor agents. VEGFR1, VEGFR2 and VEGFR3 are high affinity receptor tyrosine kinases localized in the endothelium of tumor vasculature and are involved in tumor angiogenesis. VEGFR tyrosine kinase inhibitors (TKI) block phosphorylation of the VEGFR and inhibit activation of angiogenesis and, indirectly, tumor growth. Tivozanib is a potent and selective VEGFR 1,2 & 3 TKI with a long half-life, and thus a potential novel agent in the treatment of metastatic STS. Methods: A multicenter phase II study of tivozanib in pts with metastatic and non-resectable STS was conducted through the Midwest Sarcoma Trials Partnership. Adequate performance status, organ function, measurable disease (RECIST 1.1) and 1-4 prior therapies were required. Tivozanib 1.5 mg PO daily was given in 28 day cylces (21 days on, 7 days off) until disease progression (PD) or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), assessed at 16 weeks. Secondary endpoints include overall response rate (ORR), clinical benefit rate (CBR), OS, laboratory correlates and safety and tolerability. A Simon 2-stage design was used. Results: A total of 56 pts were enrolled at 3 sites, with 53 evaluable for response. Median age was 58 (range 21-82); 57% were female; 73/27% were ECOG PS 0/1; 34/20/21/25% had 1/2/3/4 prior therapies, including 24 pts who received prior VEGF inhibitor therapy. The most common histologies included LMS (46%), pleomorphic sarcoma (14%), liposarcoma (9%) and MPNST (9%). PFS at 4 months is 34.6% with a median PFS and OS of 3.4 and 9.2 months, median follow-up 5.5 months (0.9-18.3). 2 confirmed PR, 28 SD and 22 PD were observed. ORR and CBR are 4 and 58%, respectively. Common grade 3-4 adverseevents included (%): hypertension (22), decreased EF (9) and fatigue (7). Conclusions: Tivozanib was well tolerated in this study of highly pretreated patients with multiple sarcoma histologic subtypes. Median PFS and PFS at 4 months are promising. Tivozanib warrants further study in sarcoma. Clinical trial information: NCT01782313.
Controlled Trial of Various Anti-D Dosages in Suppression of Rh Sensitization following Pregnancy: Report to the Medical Research Council by the Working Party on the Use of Anti-D Immunoglobin for the Prevention of Isoimmunization of RH-Negative Women During Pregnancy
Journal: BMJ (1974)

In a controlled trial phials containing 200 μg, 100 μg, 50 μg, or 20 μg of IgG anti-D were given to nearly 2,000 D-negative primiparae whose infants were D-positive and ABO-compatible. Only mothers whose serum lacked anti-D were included and the dose of anti-D was always given within 36 hours of delivery. Each phial contained the same total volume of immunoglobulin and the particular dose given to any patient was not known to the clinician. The anti-D content of the phials was estimated three times during the course of the trials and remained fairly constant. Six months after delivery the incidence of a positive indirect antiglobulin test result, indicating the presence of anti-D, in the four dose groups (with about 450 women in each group) was as follows: 0·22%, 0·23%, 0·44%, and 1·35%. The trend towards an increase in the frequency of failures as the dose decreases was significant at the level of P=0·02. In each dose group about 200 women were followed to the end of a second pregnancy with a D-positive infant. The failure rates (in order of decreasing dosage) as judged by a positive indirect antiglobulin test result at the second delivery were as follows: 1·5%, 1·1%, 1·5% and 2·9%. The differences between the dose groups were not statistically significant. The overall failure rate (1·7%) was about one-tenth of that expected in an untreated series. Though the results failed to prove any differences in success rates between doses of 200, 100, 50, and 20 μg of anti-D, they do suggest, in conformity with other evidence, that a dose of 20 μg is suboptimal for routine use. The results support the belief that a dose of 100 μg is adequate.
Ophthalmology
Authors: Frederick C. Blodi
Journal: JAMA (1982)

<h3>Diabetic Retinopathy</h3> One of the most important aspects in the treatment of eye diseases is the effect of photocoagulation on diabetic retinopathy. The collaborative study of the National Eye Institute has provided important and significant results.<sup>1</sup> For the first time the treatment of this condition has been put on a firm scientific basis. Additional follow-up studies have now confirmed previous reports that photocoagulation as used in the study protocol reduces the risk of severe visual loss by 50% or more. Harmful effects (decrease of vision by one or more lines, constriction of peripheral visual field) were also observed (especially when the treatment was performed with a xenon arc coagulator). However, the two-year risk of severe visual loss without treatment outweighs the harmful treatment effects in two groups: (1) in eyes with new vessels on or within one disc diameter of the optic disc equaling or exceeding one-fourth to one-third
Intracerebral hemorrhage, acute hydrocephalus, and systemic hypertension
Authors: T. H. Milhorat
Journal: JAMA (1971)

Hydrocephalus occurred as an acute complication (within four hours) of intracerebral hemorrhage in a 10-year-old girl. Following the insertion of a catheter into the cerebral ventricles, it was possible to reduce systemic hypertension and to improve the neurological condition of the patient by intermittent ventricular drainage. On the fifth day following the apoplectic event, an arteriovenous malformation of the right thalamus was surgically clipped with a satisfactory result. The following points are emphasized: acute hydrocephalus is an important and possibly common complication of intracerebral hemorrhage; in the case reported, systemic blood pressure was found to rise and fall in direct response to a rise or fall in the intraventricular pressure; and ventricular drainage was found to be useful in reducing a number of immediate complications of intracerebral hemorrhage.
Prostatectomy and survival among men with clinically localized prostate cancer
Authors: G. Lawrence
Journal: JAMA (1996)

<h3>To the Editor.</h3> —In the pooled analysis of radical prostatectomy among 2758 men at 8 major universities in United States and Europe, the authors reported high 10-year diseasespecific survival rates in all tumor grades.<sup>1</sup>However, a closer look at this extensive study permits us to understand the behavior of the tumor and improve the outcome of the most common cancer in men. At 10 years, prostate cancer deaths in grades 1, 2, and 3 were 6%, 20%, and 23% and metastases were seen in 13%, 32%, and 48%, respectively. The data cannot be improved by "watchful waiting." The results suggest patients with grades 2 and 3 disease need postoperative therapy or an alternative treatment approach. The fact that these patients are poor candidates for surveillance is conceded even by its proponents. Results for patients with grade 1 tumors at 10 years are good. Low-grade tumors have a low mitotic index—ie, few mitotic
Metric Measurements: Change in JAMA Policy
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ORAL CANDIDIASIS
Authors: M. J. Marples
Journal: British Journal of Dermatology (1968)

Journal Article ORAL CANDIDIASIS Get access M. J. Marples M. J. Marples Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 80, Issue 1, 1 January 1968, Pages 58–59, https://doi.org/10.1111/j.1365-2133.1968.tb11907.x Published: 01 January 1968
Fatty-acid Analysis of Meningiomas by Gas-Phase Chromatography
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic Standards of Tuberculosis—Revised
Authors: John G. Weg
Journal: JAMA (1976)

THE NEW "Diagnostic Standards and Classification of Tuberculosis and other Mycobacterial Diseases"<sup>1</sup>represents a major departure from previous classifications that evolved on the basis of scientific advances over the last 100 years. It reflects the results of more than two decades of experience with chemotherapy, which now can cure a very serious disease that formerly carried a lifelong threat of exacerbation and a mortality exceeding that of many cancers. The new classification is based on the pathogenesis of tuberculosis. It is applicable to all in whom the diagnosis of tuberculosis is or should be considered. Characteristics have been selected that (1) assure an accurate diagnosis (ideally the identification of tubercle bacilli), (2) coincide with the appropriate medical response, whether it be no response, preventive therapy, or chemotherapy, (3) correlate best with prognosis, (4) contain necessary information for public health action, and (5) provide a uniform, functional, and practical means
Gastroesophageal hypercontracting sphincter. Manometric and clinical characteristics
Authors: J. M. Garrett
Journal: JAMA (1969)

Eleven of 381 patients who underwent diagnostic esophageal-motility tests were found to have a "hypercontracting sphincter" characterized by prolonged and powerful contractions of the gastroesophageal sphincter. Other motility disturbances included esophageal motor incoordination, diffuse spasm of the esophagus in two patients, and pressure changes of hiatal hernia, which were present in six patients. Substernal pain, occasionally thought to be of cardiac origin, and dysphagia were prominent complaints in nine of the patients, while two patients had no gastrointestinal-tract symptoms. Reassurance, symptomatic treatment, and medical management of hiatal hernia were generally effective, but because of incapacitating pain in two patients, esophagomyotomy was performed and provided excellent relief of symptoms. A hypercontracting gastroesophageal sphincter should be considered in patients with unexplained chest pain, since the diagnosis, made only by manometry, will allow appropriate and effective treatment.
Effect of hysterectomy on bowel function.
Journal: BMJ (1989)

dispense with inpatient beds altogether.Even when intensive care is given by enthusiastic and committed staff with residential care facilities outside hospital psychiatric admissions will always be needed.''" Prob- ably a greater proportion of those who need admission will be more disturbed as others can be dealt with outside hospital.This has been our experience and has economic implications. 15lthough generalising from services in one part of the country to another is difficult, Nottingham is representative of areas with middling demand.Its use of psychiatric beds for the 15-65 age group in 1980 was close to the mean of 0 45 bed per 1000 population estimated by Hirsch to reflect the requirements of England and Wales as a whole.'6If the fall to the 1985 rate in Nottingham was reflected nationally the requirements for beds would be reduced by over a third.Our findings of reduced use of beds should not be interpreted as showing the newer service to be superior; that is the subject of a separate investigation.Nevertheless, we conclude with some confidence that when community and hospital psychiatric services are combined in an integrated model the benefits are quickly shown and economically feasible.
Histology
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Review of Harmful Gastrointestinal Effects of Carrageenan in Animal Experiments
Authors: Joanne K. Tobacman
Journal: Environmental Health Perspectives (2001)

In this article I review the association between exposure to carrageenan and the occurrence of colonic ulcerations and gastrointestinal neoplasms in animal models. Although the International Agency for Research on Cancer in 1982 identified sufficient evidence for the carcinogenicity of degraded carrageenan in animals to regard it as posing a carcinogenic risk to humans, carrageenan is still used widely as a thickener, stabilizer, and texturizer in a variety of processed foods prevalent in the Western diet. I reviewed experimental data pertaining to carrageenan's effects with particular attention to the occurrence of ulcerations and neoplasms in association with exposure to carrageenan. In addition, I reviewed from established sources mechanisms for production of degraded carrageenan from undegraded or native carrageenan and data with regard to carrageenan intake. Review of these data demonstrated that exposure to undegraded as well as to degraded carrageenan was associated with the occurrence of intestinal ulcerations and neoplasms. This association may be attributed to contamination of undegraded carrageenan by components of low molecular weight, spontaneous metabolism of undegraded carrageenan by acid hydrolysis under conditions of normal digestion, or the interactions with intestinal bacteria. Although in 1972, the U.S. Food and Drug Administration considered restricting dietary carrageenan to an average molecular weight > 100,000, this resolution did not prevail, and no subsequent regulation has restricted use. Because of the acknowledged carcinogenic properties of degraded carrageenan in animal models and the cancer-promoting effects of undegraded carrageenan in experimental models, the widespread use of carrageenan in the Western diet should be reconsidered.